Nanomaterials for theranostics: Recent advances and future challenges

Eun Kyung Lim, Taekhoon Kim, Soonmyung Paik, Seungjoo Haam, yongmin Huh, Kwangyeol Lee

Research output: Contribution to journalReview article

551 Citations (Scopus)

Abstract

Theranostics as a treatment strategy for individual patients encompasses a wide range of subjects, including personalized medicine, pharmacogenomics, and molecular imaging, in order to develop an efficient new targeted therapy and optimize drug selection via a better molecular understanding. Furthermore, theranostics aims to monitor the response to the treatment, to increase drug efficacy and safety, and to eliminate the unnecessary treatment of patients, resulting in significant cost savings for the overall healthcare system. Highly characteristic and nonrandom mutation patterns are found in well-studied oncogenes and tumor suppressor genes. Oncogenes are recurrently mutated at the same amino acid positions, leading to increased activity of the corresponding proteins.

Original languageEnglish
Pages (from-to)327-394
Number of pages68
JournalChemical Reviews
Volume115
Issue number1
DOIs
Publication statusPublished - 2015 Jan 14

Fingerprint

Nanostructured materials
Molecular imaging
Pharmaceutical Preparations
Medicine
Tumors
Genes
Amino Acids
Costs
Proteins
Pharmacogenetics

All Science Journal Classification (ASJC) codes

  • Chemistry(all)

Cite this

Lim, Eun Kyung ; Kim, Taekhoon ; Paik, Soonmyung ; Haam, Seungjoo ; Huh, yongmin ; Lee, Kwangyeol. / Nanomaterials for theranostics : Recent advances and future challenges. In: Chemical Reviews. 2015 ; Vol. 115, No. 1. pp. 327-394.
@article{3d7c3a56ac354e69ae071b55eb249e65,
title = "Nanomaterials for theranostics: Recent advances and future challenges",
abstract = "Theranostics as a treatment strategy for individual patients encompasses a wide range of subjects, including personalized medicine, pharmacogenomics, and molecular imaging, in order to develop an efficient new targeted therapy and optimize drug selection via a better molecular understanding. Furthermore, theranostics aims to monitor the response to the treatment, to increase drug efficacy and safety, and to eliminate the unnecessary treatment of patients, resulting in significant cost savings for the overall healthcare system. Highly characteristic and nonrandom mutation patterns are found in well-studied oncogenes and tumor suppressor genes. Oncogenes are recurrently mutated at the same amino acid positions, leading to increased activity of the corresponding proteins.",
author = "Lim, {Eun Kyung} and Taekhoon Kim and Soonmyung Paik and Seungjoo Haam and yongmin Huh and Kwangyeol Lee",
year = "2015",
month = "1",
day = "14",
doi = "10.1021/cr300213b",
language = "English",
volume = "115",
pages = "327--394",
journal = "Chemical Reviews",
issn = "0009-2665",
publisher = "American Chemical Society",
number = "1",

}

Nanomaterials for theranostics : Recent advances and future challenges. / Lim, Eun Kyung; Kim, Taekhoon; Paik, Soonmyung; Haam, Seungjoo; Huh, yongmin; Lee, Kwangyeol.

In: Chemical Reviews, Vol. 115, No. 1, 14.01.2015, p. 327-394.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Nanomaterials for theranostics

T2 - Recent advances and future challenges

AU - Lim, Eun Kyung

AU - Kim, Taekhoon

AU - Paik, Soonmyung

AU - Haam, Seungjoo

AU - Huh, yongmin

AU - Lee, Kwangyeol

PY - 2015/1/14

Y1 - 2015/1/14

N2 - Theranostics as a treatment strategy for individual patients encompasses a wide range of subjects, including personalized medicine, pharmacogenomics, and molecular imaging, in order to develop an efficient new targeted therapy and optimize drug selection via a better molecular understanding. Furthermore, theranostics aims to monitor the response to the treatment, to increase drug efficacy and safety, and to eliminate the unnecessary treatment of patients, resulting in significant cost savings for the overall healthcare system. Highly characteristic and nonrandom mutation patterns are found in well-studied oncogenes and tumor suppressor genes. Oncogenes are recurrently mutated at the same amino acid positions, leading to increased activity of the corresponding proteins.

AB - Theranostics as a treatment strategy for individual patients encompasses a wide range of subjects, including personalized medicine, pharmacogenomics, and molecular imaging, in order to develop an efficient new targeted therapy and optimize drug selection via a better molecular understanding. Furthermore, theranostics aims to monitor the response to the treatment, to increase drug efficacy and safety, and to eliminate the unnecessary treatment of patients, resulting in significant cost savings for the overall healthcare system. Highly characteristic and nonrandom mutation patterns are found in well-studied oncogenes and tumor suppressor genes. Oncogenes are recurrently mutated at the same amino acid positions, leading to increased activity of the corresponding proteins.

UR - http://www.scopus.com/inward/record.url?scp=84922242284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922242284&partnerID=8YFLogxK

U2 - 10.1021/cr300213b

DO - 10.1021/cr300213b

M3 - Review article

C2 - 25423180

AN - SCOPUS:84922242284

VL - 115

SP - 327

EP - 394

JO - Chemical Reviews

JF - Chemical Reviews

SN - 0009-2665

IS - 1

ER -